Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Brescia
Clinical trial register · Italy

Clinical Trials in Brescia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Brescia

21 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 2
32
Ranica, Brescia, Pavia
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Bologna, Brescia, Milan
2026-03-24
Recruiting
Novartis Pharmaceuticals
Observational
50
Alessandria, Avellino, Brescia, Florence, Genova, Milan, Palermo, Roma
2026-01-13
Recruiting
Novartis Pharmaceuticals
Observational
250
Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina
2025-12-17
Recruiting
Novartis Pharmaceuticals
Observational
300
Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia
2025-07-30
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa
2025-01-31
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals
Phase 2
21
Ancona, Brescia, Monza, Milan, Rozzano, Verona
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Ancona, Bergamo, Brescia, Genova, Milan, Pescara, Perugia, Pisa
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Bari, Ranica, Brescia, Milan, Roma, Torino, Naples
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 3
200
Brescia, Catania, Florence, Pavia, Roma, Naples
2023-05-11
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Brescia, Rozzano
2023-05-08
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Ancona, Brescia, Caserta, Chieti, Catanzaro, Florence, Chiavari, Genova
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Brescia, Florence, Genova, Milan, Roma
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Bergamo, Bologna, Brescia, Ferrara, Florence, Meldola, Milan, Monza
2021-04-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Brescia, Milan
2021-02-24
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Bergamo, Bologna, Brescia, Meldola, Monza, Milan, Rozzano, Modena
2015-12-11
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Ancona, Bari, Bologna, Brescia, San Giovanni Rotondo, Florence, Milan, Rozzano
2015-03-05
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-italy/city/brescia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Brescia that also match the filters currently applied.

How many clinical trials are recruiting in Brescia?

10 of the 21 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Brescia), 21 studies
PhaseStudiesRecruitingShare
Phase 39542.9%
Phase 25223.8%
Observational3314.3%
Phase 4209.5%
Phase 1104.8%
Phase 1/2104.8%

Most active sponsors

Lead sponsors with the most studies (Brescia)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals2110
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.